It showed that 1 mg Ozempic led to a 24 per cent reduced risk of worsening kidney disease and kidney failure (end-stage ...

In an important regulatory win for Denmark’s Novo Nordisk, the US Food and Drug Administration (FDA) yesterday approved ...

The U.S. Food and Drug Administration (FDA) has granted approval for an expanded use of Ozempic® (semaglutide) injection, ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

Ozempic is a solution for subcutaneous injection that’s approved by the Food and Drug Administration (FDA) to: An interaction occurs when one substance causes another substance to have a ...

This approval, along with its existing indications for adults with type 2 diabetes to improve glycemic control and to reduce the risk of major cardiovascular events in adults also with known heart ...

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...

Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing kidney failure risk, disease progression, and death due to ...